We are live on ! Find out more
AMED

Amedisys

Delisted

AMED was delisted on the 14th of August, 2025.

281 hedge funds and large institutions have $2.32B invested in Amedisys in 2023 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 106 increasing their positions, 96 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

265% more call options, than puts

Call options by funds: $6.04M | Put options by funds: $1.65M

27% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 33

10% more repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 96

1% more funds holding

Funds holding: 277281 (+4)

0.88% more ownership

Funds ownership: 95.72%96.6% (+0.88%)

10% less capital invested

Capital invested by funds: $2.56B → $2.32B (-$249M)

Holders
281
Holders Change
+4
Holders Change %
+1.44%
% of All Funds
4.48%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
42
Increased
106
Reduced
96
Closed
33
Calls
$6.04M
Puts
$1.65M
Net Calls
+$4.38M
Net Calls Change
+$4.86M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$238M +$8.81M +101,857 +3%
BlackRock
2
BlackRock
New York
$223M -$92.5M -1,069,523 -26%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$191M -$17.6M -203,387 -7%
JP Morgan Chase
4
JP Morgan Chase
New York
$147M +$20.5M +237,160 +13%
RP
5
Riverbridge Partners
Minnesota
$112M -$50.4K -582 -0%
DM
6
Deerfield Management
New York
$109M +$30M +347,099 +31%
Mackenzie Financial
7
Mackenzie Financial
Ontario, Canada
$76.6M +$37.9K +438 +0%
State Street
8
State Street
Massachusetts
$67.9M +$2.46M +28,434 +3%
Ameriprise
9
Ameriprise
Minnesota
$59.7M -$23.4M -270,594 -25%
Schroder Investment Management Group
10
Schroder Investment Management Group
United Kingdom
$42M +$8.58M +99,219 +21%
BG
11
Bellevue Group
Switzerland
$39.9M -$6.13M -70,896 -12%
CS
12
Credit Suisse
Switzerland
$39.2M +$100K +1,156 +0.2%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$37.4M +$8.43M +97,488 +24%
Citadel Advisors
14
Citadel Advisors
Florida
$37.1M +$20.6M +237,826 +89%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$35.6M +$1.32M +15,231 +3%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$34.5M -$11.5M -133,408 -22%
VLKIM
17
Van Lanschot Kempen Investment Management
Netherlands
$34.5M +$2.14M +24,756 +6%
Boston Partners
18
Boston Partners
Massachusetts
$32M +$9.06M +104,737 +32%
Millennium Management
19
Millennium Management
New York
$28.7M -$7.61M -87,955 -18%
Charles Schwab
20
Charles Schwab
California
$26M +$1.19M +13,768 +4%
Westfield Capital Management
21
Westfield Capital Management
Massachusetts
$25.2M +$1.15M +13,271 +4%
Principal Financial Group
22
Principal Financial Group
Iowa
$24M +$152K +1,761 +0.5%
Norges Bank
23
Norges Bank
Norway
$23.8M +$1.09M +12,624 +4%
Northern Trust
24
Northern Trust
Illinois
$22.8M -$25K -289 -0.1%
Alyeska Investment Group
25
Alyeska Investment Group
Illinois
$20.8M +$24.4M +282,461 New

AMED Hedge Fund Activity: Q1 2023 in Review

281 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q1 2023, worth a combined $2.32B — down 9.7% from $2.56B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new AMED positions and 33 closed out — a net gain of 9 holders — while 106 added to existing stakes and 96 trimmed.

The largest buyer was Deerfield Management, adding an estimated $30M. The largest seller was BlackRock, cutting an estimated $92.5M.

  • 281 institutional investors held Amedisys (AMED) as of Q1 2023, up from 277 in Q4 2022.
  • Funds reported $2.32B of Amedisys stock for Q1 2023, down 9.7% quarter-over-quarter.
  • 42 funds opened new Amedisys positions in Q1 2023 and 33 closed out, a net change of +9 holders.
  • The largest Amedisys buyer in Q1 2023 was Deerfield Management, an estimated $30M added.
  • The largest Amedisys seller in Q1 2023 was BlackRock, an estimated $92.5M sold.

Based on aggregated 13F filings for Q1 2023.